Related Experiment Video
Updated: May 9, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells
Jae-Young Kim1, Eric A Welsh, Umut Oguz
1Department ofThoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Abstract:
TANK-binding kinase 1 (TBK1) has emerged as a novel therapeutic target for unspecified subset of lung cancers. TBK1 reportedly mediates prosurvival signaling by activating NF-κB and AKT. However, we observed that TBK1 knockdown also decreased viability of cells expressing constitutively active NF-κB and interferon regulatory factor 3. Basal phospho-AKT level was not reduced after TBK1 knockdown in TBK1-sensitive lung cancer cells, implicating that TBK1 mediates unknown survival mechanisms. To gain better insight into TBK1 survival signaling, we searched for altered phosphoproteins using mass spectrometry following RNAi-mediated TBK1 knockdown. In total, we identified 2,080 phosphoproteins (4,621 peptides), of which 385 proteins (477 peptides) were affected after TBK1 knockdown. A view of the altered network identified a central role of Polo-like kinase 1 (PLK1) and known PLK1 targets. We found that TBK1 directly phosphorylated PLK1 in vitro. TBK1 phosphorylation was induced at mitosis, and loss of TBK1 impaired mitotic phosphorylation of PLK1 in TBK1-sensitive lung cancer cells. Furthermore, lung cancer cell sensitivity to TBK1 was highly correlated with sensitivity to pharmacological PLK inhibition. We additionally found that TBK1 knockdown decreased metadherin phosphorylation at Ser-568. Metadherin was associated with poor outcome in lung cancer, and loss of metadherin caused growth inhibition and apoptosis in TBK1-sensitive lung cancer cells. These results collectively revealed TBK1 as a mitosis regulator through activation of PLK1 and also suggested metadherin as a putative TBK1 downstream effector involved in lung cancer cell survival.
Insights
TANK-binding kinase 1 (TBK1) regulates lung cancer cell survival by activating Polo-like kinase 1 (PLK1) during mitosis. This study reveals TBK1
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- TANK-binding kinase 1 (TBK1) is a potential therapeutic target in lung cancer.
- TBK1 is known to activate NF-κB and AKT for cell survival.
- However, TBK1's precise role in lung cancer survival pathways remains unclear.
Purpose of the Study:
- To elucidate novel survival mechanisms mediated by TBK1 in lung cancer.
- To identify downstream targets of TBK1 signaling.
- To investigate the role of TBK1 in cell division and its correlation with therapeutic sensitivity.
Main Methods:
- RNA interference (RNAi)-mediated TBK1 knockdown.
- Mass spectrometry-based phosphoproteomics to identify altered phosphoproteins.
- In vitro kinase assays to assess direct phosphorylation.
- Correlation analysis between TBK1 sensitivity and PLK1 inhibitor sensitivity.
- Immunoblotting to detect protein phosphorylation.
Main Results:
- TBK1 knockdown affected 385 phosphoproteins, highlighting a central role for Polo-like kinase 1 (PLK1).
- TBK1 directly phosphorylates PLK1 at mitosis, and TBK1 loss impairs this phosphorylation.
- Lung cancer cell sensitivity to TBK1 inhibition correlates with sensitivity to PLK1 inhibitors.
- TBK1 knockdown reduced metadherin phosphorylation, and metadherin loss induced apoptosis in sensitive cells.
Conclusions:
- TBK1 acts as a mitosis regulator by activating PLK1.
- Metadherin is a potential downstream effector of TBK1 involved in lung cancer cell survival.
- Targeting TBK1 may offer a therapeutic strategy for lung cancer by disrupting mitosis and survival signaling.
More Related Videos
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor (LATS) Biosensor
Published on: September 13, 2018
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018